While the United States Drug Enforcement Administration (DEA) classifies psychedelic compounds as Schedule 1 drugs, these regulatory hurdles can be addressed by scientific discovery. To conduct research with these drugs, scientists need many layers of regulatory approvals that also may require upgrades to security protocols in labs, all of which can be expensive. Such obstacles make private philanthropy essential to 1) advancing comprehensive investigations into the potential therapeutic properties of these compounds, and 2) ensuring sustainable resources for scientific studies and programs dedicated to reframing conversations around psychedelic science.
